Cobra Biomanufacturing, a manufacturer of biopharmaceuticals, has announced its agreement with a European biotechnology company to provide development services for an Adenovirus-based product.
Central to the contract will be the application of Cobra's virus-purification platform, which is based on scalable chromatographic operations and integrates single-use technologies throughout.
The process shows comparable purities to density gradient approaches and yields of up to 50 per cent.
